Chronic hepatitis C infection in the USA is a highly morbid condition and current guidelines recommend one-time screening among the birth cohort . Understanding strategies to optimize screening can help inform future hepatitis C virus (HCV) screening guidelines. A focused literature search was performed using PubMed and manual abstract review from major hepatology conferences over the past 2 years. The search strategy involved using Medical Subject Headings terms for hepatitis C, screening, birth cohort, baby boomers, and 1945-1965. The review was limited to data from the USA. A total of 327 articles were identified and 36 abstracts were included, with studies published between 2012-2019. Strategies including clinician education, electronic medical record alerts, reflex HCV RNA testing, point-of-care testing, multisite (outpatient, inpatient, emergency department, endoscopy suite) initiatives, direct patient solicitation, and utilization of non-physician providers have increased HCV screening rates. However, broad implementation remains less than optimal. Barriers include lack of patient acceptance to screening and engagement in the HCV care cascade. The Veterans Affairs Healthcare System has achieved higher birth cohort screening rates through an integrated approach requiring high-level engagement by leadership and institutional commitment. Multiple strategies for increasing birth cohort screening have been successful, but overall rates of HCV screening remain low. These strategies can inform public health efforts to implement emerging national recommendations for expansion of HCV screening to all U.S. adults age 18 or older. Citation of this article: Tsay CJ, Lim JK. Assessing the effectiveness of strategies in US birth cohort screening for hepatitis C infection.
Introduction
Chronic hepatitis C virus (HCV) infection is one of the most common indications for liver transplantation and the leading cause of hepatocellular carcinoma in the USA, accounting for approximately 19,000 deaths annually and substantial healthcare costs. 1 An estimated 4.1 million individuals in the USA are HCV antibody (Ab)-positive, indicative of past or current infection. Among those, approximately 2.4 million individuals have ongoing chronic HCV infection with positive HCV RNA. 2 The baby boomer "birth cohort" of individuals born 1945-1965 comprise approximately 75% of HCV infections in the USA despite representing only 27% of the general population. 3 One study in 2012 retrospectively applied birth cohort to previously risk-based HCV screening using the National Health and Nutrition Examination Survey (NHANES) database and determined that optimal application of risk-based guidelines would identify 82% of chronic HCV cases (number needed to screen 14.6) compared to birth-cohort screening, which would identify 76% of chronic HCV cases (number needed to screen 28.7). 4 The Center for Disease Control (CDC) and the USA Preventative Services Task Force (USPSTF) issued recommendations in 2012 3, 5 and 2013 6, 7 recommending one-time universal screening in all individuals born between 1945-1965, irrespective of symptoms or risk factors. Cost effectiveness studies have confirmed birth cohort screening to be cost saving for billions in test and treat models. 5 However, recent studies indicate that HCV testing in the birth cohort minimally increased from 12.3% to 17.3% between 2013 and 2017. 8 One unique population, veterans being cared for at the Veteran Affairs Healthcare System, achieved more successful screening through automated clinical reminders through the electronic medical record (EMR) and also increased awareness among primary care providers through national directives. One study reported 79.5% of veterans born between 1945-1965 had been tested for the HCV Ab. 9 Given the high cost and mortality associated with HCV, coupled with the presence of effective treatment options with direct-acting antivirals (DAAs), identification of patients with HCV is of paramount importance to public health efforts to achieve HCV elimination. The success of the World Health Organization campaign for global elimination of HCV infection by 2030 10, 11 will depend on optimization of the HCV care cascade from screening/identification to linkage to treatment, 12 and the associated funding required to support hepatitis programs. 13 cohort . Although there have been substantial efforts on HCV microelimination in several global regions, this article focuses primarily on evidence from the USA. Understanding existing strategies for optimization of 1945-1965 birth cohort screening may help inform future guidelines for public health interventions focused on HCV screening, particularly in the context of the burgeoning opioid epidemic.
Methods
A focused literature search was performed using PubMed, with a combination of search terms, including screen, test, hepatitis C virus, HCV, hepatitis C, birth cohort, 1945-1965, and baby boomer, in August 2019. Manual abstract review was performed (C.T.) for major hepatology conferences, including The Liver Meeting 2017-2018 of the American Association for the Study of Liver Diseases, Digestive Diseases Week 2017-2019, and The International Liver Congress of the European Association for the Study of the Liver 2017-2019. The review was limited to USA data, with the exception of reports from six countries (Argentina, Chile, Finland, France, Greece, and Japan) 14 with similar recommendations for birth cohort screening or one-time screening for all ages. There was no time restriction imposed on the search strategy of original manuscripts.
Results
A total of 327 full text papers were identified by the database search and an additional 38 abstracts per manual review from major conferences. After individual assessment of abstracts, 36 were included in the review. Study characteristics and outcomes are summarized below ( Table 1 ). All papers were published 2012-2019 but one study from 2012 was excluded due to assessment prior to implementation of CDC birth cohort recommendations. 15 
Current state of hepatitis C screening in the USA
The current recommendations of the CDC and USPTF regarding HCV screening are summarized as follows:
CDC (August 17, 2012): In addition to testing adults of all ages at risk for HCV infection, the CDC recommends:
All adults born during 1945-1965 receive one-time testing for the HCV. Testing should begin with anti-HCV. If the anti-HCV test is positive, or reactive, then a nucleic acid test should follow. All persons identified with current HCV infection should receive a brief alcohol screening and intervention, as clinically indicated, followed by referral to appropriate care and treatment services. 5
USPSTF (June 25, 2013) recommends:
Screening for HCV infection in persons at high risk for infection. One-time screening for HCV infection in adults born between 1945 and 1965.
These recommendations were in line with recommendations of the Institute of Medicine and the USA Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. 16 Subsequent studies confirmed the cost-effectiveness of birth cohort testing based on health economic models, which projected that an additional 808,580 cases of chronic HCV infection cases would be identified at a cost of $2874 per case, and that even with a test-and-treat strategy using historical DAA plus pegylated interferon/ribavirin, quality adjusted life-years increased by $532,000, with an incremental cost-effectiveness ratio of $35,700 per quality adjusted life-years saved. 17 Despite implementation of these recommendations in 2012-2013, a recent review suggested that there was only a modest increase in HCV screening within the birth cohort in the USA, estimated to have risen from 12.3% in 2013 to 17.3% in 2017. 8 Further analysis of this dataset identified the primary care clinic as the setting in which prioritization of testing should occur, permitting unscreened or untested eligible patients access to follow-up care within the outpatient clinic. 18 This information underlines the need for more innovative screening strategies to be implemented which involve a combination of patient and provider education, harnessing the electronic health record automated alerts in the inpatient, outpatient, emergency departments, endoscopy, and colonoscopy suites, as well as a patient-centered medical home approach 19 utilizing non-physician providers to assist in improving screening, reflex testing, and linkage of care to the HCV care cascade.
Innovative strategies for screening

EMR alerts
The advent of the EMR or electronic health record has created a platform in which screening can become more streamlined with patient care in both the outpatient and inpatient settings. Additionally, several states, including New York, Connecticut, Massachusetts, California, and Colorado, have established laws mandating that baby boomers be offered screening with a one-time HCV Ab test. In New York state, laboratory data confirmed a 51% increase in the number of specimens collected for HCV testing among birth cohort individuals between 2013 and 2014, and New York Medicaid data revealed a 52% increase in average monthly testing for HCV Ab from 2012 to 2014 20 despite exclusion of HCV testing requirement in the emergency department (ED) setting. 21 Furthermore, while EMR appears to be a cornerstone for automated alerts, given the simplicity of identifying screening candidates based solely on date of birth, additional strategies to augment EMR-based testing have resulted in significant increases in screening rates, including one study employing targeted education of resident physicians which found an increase from 62% at baseline to 81% at 6 months postintervention. 22 Similar increases in screening rates employing education plus EMR reminders in a resident physician context resulted in up to a 3-fold increase in HCV testing rates. [23] [24] Outpatient Primary care and outpatient specialty clinics are the cornerstone of population-based screening and the focus of most EMR alert-based interventions. Multiple studies have reported increases in HCV screening rates after implementation of EMR alerts [25] [26] [27] [28] [29] [30] [31] in multiple quality improvement interventions, including those incorporating formal Plan, Do, Study, Act cycles; although, the magnitude of increase has ranged widely from increases of 1.8-to 15.8-fold. 32, 33 Two studies examined the impact of educational intervention for outpatient primary care providers versus EMR alerts alone, and found an increase in screening rates as high as 45% to 55% at 3 months after a single education session. 28, 34 While EMR alerts represent an easily adapted, systems-based intervention to increase birth cohort screening, current studies have been limited to largely small single-center interventions in unique clinical settings, with limited information on downstream outcomes within the care cascade, including RNA confirmation, linkage to care, and HCV treatment. One of the few multicenter studies examining outpatient screening interventions was reported by Turner et al. 35 who evaluated the feasibility and impact of the Reach, Effectiveness, Adoption, Implementation, Maintenance model in a state-funded program to implement birth cohort testing in five federally qualified healthcare centers and one family medicine residency program. Within a cohort of 27, 700 baby boomers born 1945-1965, 13,334 (48.1%) successfully underwent HCV Ab testing, 695 were HCV Ab-positive (5.2%), 349 were HCV RNA-positive (2.6%), 82 initiated DAA therapy, 74 completed DAA therapy, and 70 achieved a sustained virologic response (SVR). In this grant funded intervention study involving multilevel practice engagement strategies, patient navigation, standardized HCV Ab and reflex HCV RNA testing, and access to free DAA therapy via prescription assistance programs, HCV birth cohort screening increased from 0.8% to 48.1% between 2014 and 2018. This study additionally identified multiple barriers and challenges to birth screening interventions, significant site-level variability in performance, and the central importance of best practice alerts (BPAs), reflex RNA testing, access to specialty consultation via telemedicine, and role of local champions.
Inpatient
The inpatient setting provides a unique place for birth cohort screening. Multiple studies have demonstrated that inpatient screening is effective in identifying new cases of HCV but may not translate to effective linkage to care or treatment, and is limited by factors such as socioeconomic status, racial disparities, and lack of insurance. 36, 37 Two studies examined the effect of the 2014 New York state HCV screening law within large academic hospitals and showed that despite a significant increase in screening rates, 8 to 39% and 53 to 84%, respectively, very few patients were linked to care or received DAA treatment, with an overall decrease in treatment initiation during the period of observation. 38 The challenges of inpatient screening may be driven by variable access to reflex RNA testing, provider-led results reporting and education, and outpatient follow-up after hospital discharge, and underscores the need for additional research to clarify evidence-based strategies to augment linkage to care.
Direct patient solicitation
Multiple strategies targeted at direct patient contact have been explored to increase screening rates, including direct mail campaigns, with letters containing educational material and blood test request forms distributed to birth cohort patients identified via EMR. 39, 40 One study compared liveperson recruitment through either phone call, direct mail, or electronic health record prompt at three study sites and found that all three methods were significantly limited by requirement for substantial administrative and staffing resources beyond existing clinic infrastructure. One randomized controlled trial assigned patients to one of three independent implementation strategies: repeated mailings, BPA through electronic health record, or direct phone solicitation. 41 Compared to controls, all three methods were associated with increased screening, with repeat mailings, BPA, and direct phone solicitation resulting in 8 times, 2.6 times, and 5 times control rates, respectively, suggesting that direct patient contact may represent a valuable, complementary tool to augment birth cohort screening efforts.
Colonoscopy
Patients undergoing routine colonoscopy for colorectal cancer screening overlap with patients born 1945-1965 (age 54-74 years as of 2019). This concordance of age makes point-ofcare testing (POCT) in the colonoscopy suite a unique setting for HCV screening. Abu-Heija et al. 42, 43 reported the results of a retrospective cohort study of a predominantly African American population undergoing colonoscopy in an urban openaccess colonoscopy suite, and identified an increase in birth cohort HCV testing from 31% to 40.3% between 2014-2017, high rates of HCV Ab positivity (31.5 to 42.9%), and higher likelihood of screening among patients referred from university-affiliated clinicians. Another study performed in USA veterans examined the impact of a same-day HCV testing during colonoscopy which involved registered nurse pre-screening and phone consent for HCV Ab testing in birth cohort patients 1 day prior to scheduled colonoscopy, followed by laboratory draw at the time of intravenous line placement for colonoscopy; this intervention resulted in an 85% HCV Ab testing rate in this setting. 44 Other studies have reported slightly lower rates for HCV Ab testing among patients undergoing colonoscopy targeted on the basis of risk factors identified by patient survey. 45, 46 Endoscopy Outside the specific context of colorectal cancer screening, the endoscopy suite broadly provides an opportunity for HCV screening by gastroenterologists who are uniquely positioned to offer real-time Ab testing, results reporting, patient education, and linkage to care including DAA treatment. Few studies have examined prospective interventions in the endoscopy suite incorporating both birth cohort-and risk factor-based testing. One urban safety-net hospital in California conducted a series of studies 47, 48 to examine HCV screening practices in the endoscopy suite setting, and identified lower test acceptance among birth cohort versus nonbirth cohort populations (odds ratio: 0.39, 95% confidence interval: 0.13-1.14, p=0.09) 48 and 82.5% versus 93.9% (p=0.004). 47 Integration of a pre-screening tool and a patient navigator tool in the outpatient endoscopy suite resulted in an overall increase in eligible patients who were tested (50.8% to 77.9%); although, the authors identified a persistent gap in HCV testing in positive risk factor groups, as well as significant challenges in achieving patient acceptance and engagement. 49 
ED
Historic studies of HCV screening in ED populations prior to implementation of birth cohort screening guidelines revealed a higher prevalence than in the general population, with rates ranging from 4% in Michigan to 18% in Baltimore. [50] [51] [52] [53] [54] [55] Although our review focused specifically on patients within the 1945-1965 year-range, some studies have revealed that testing restricted to the birth cohort alone may miss identification of up to 28% of HCV Ab-positive patients seen in the ED setting. 56 Recent reports have additionally identified high levels of patient acceptance of HCV testing in the ED setting Journal of Clinical and Translational Hepatology 2020 vol. 8 | 25-41 (90% of those completed a structured interview), but sobering low rates of linkage to care following testing among Ab positive patients. 54, 57 A large CDC-funded study conducted in an urban academic ED center in Alabama demonstrated similarly high patient acceptance of HCV testing (88%), high HCV Ab positivity (11%), and high HCV RNA testing of Ab positive patients (88%). 58 However, among patients confirmed with chronic HCV infection (68% RNA positive among Ab-positive group), only 54% attended a hepatology clinic appointment following discharge despite automated phone calls and a care coordinator focused on linkage to care. Another study examining HCV testing of birth cohort versus all adults in an urban ED in California revealed higher HCV Ab positivity in birth cohort versus all adults (13.7% vs. 10.3%), limited HCV RNA confirmation testing (67%), similar proportion of HCV RNA-positive patients confirmed with chronic infection (70%), and poor linkage to care, with only 24% of RNA positive individuals attending a postdischarge clinic appointment. 59 A recent study in a large urban academic ED in Boston similarly revealed high HCV Ab positivity (13.2%) and poor attendance at postdischarge clinic appointment (22.5%) among HCV RNA-positive patients. 60 These findings underscore the high yield of targeted HCV screening in the ED context, as well as the need for innovative strategies to augment linkage to care to promote more effective patient navigation.
Non-physician providers
Non-physician clinicians including nurses, care coordinators, patient navigators, pharmacists, and advanced practice providers, such as physician assistants, nurse practitioners, and advance practice registered nurses, play a central role in all aspects of HCV screening, care navigation, and treatment, and have featured prominently in nearly all interventional studies targeting birth cohort screening. However, few studies have examined the specific roles of non-physician providers. Shelgrove et al. 61 highlighted the importance of care coordinators and clinic managers in the context of a federally qualified healthcare centers in California, with a focus on augmenting linkage to care. Among a cohort of patients screened for HCV, 7.5% were HCV Ab-positive (410/5481), of whom 45% were HCV RNA-positive with reflex testing (183/410), and 92% (164/183) successfully attended an appointment with either a primary care physician or specialist following diagnosis of chronic HCV infection; these findings contrast sharply with the comparatively low rates of linkage to care (22.5-37.3%) reported in other studies, such as the CDC Hepatitis Testing and Linkage to Care initiative. 60, 62, 63 Utilizing medical assistants to identify eligible patients for HCV screening by means of printed patient intake forms within an outpatient primary care clinic resulted in increased testing rates, from 5% up to 23%. 64 Another research group reported the novel use of clinical pharmacists to offer pointof-care HCV Ab testing to high risk and birth cohort patients seen at a community-based pharmacy. 65 It is likely that a combination of interventions using physician and non-physician providers across practice settings will be necessary to meaningfully expand HCV screening in both birth cohort and high-risk populations.
Birth cohort screening in USA veterans
The USA Veterans Health Administration (VHA) has represented a national leader in efforts to screen and manage HCV using systems-based approaches. One early retrospective cohort study from 2011 in the Atlanta Veterans Affairs Medical Center described that over half of birth cohort veterans in care had been tested for HCV, and those born in the birth cohort were 6 times more likely to have a positive HCV Ab test and 3 times more likely to have chronic HCV compared to non-birth cohort veterans. 66 A 2016 report examined HCV testing practices within the national VHA system among 4.2 million birth cohort veterans receiving care between 2000-2013, and confirmed that 51% had undergone HCV testing; significant local and regional variabilities in testing practices (7-83%) were identified, and up to 20% of birth cohort veterans with FIB-4 scores suggestive of advanced fibrosis or cirrhosis had not received HCV testing. 67 In the context of national efforts by Veterans Affairs' leadership to adopt birth cohort HCV screening recommendations, HCV Ab testing in birth cohort veterans had increased to nearly 70% as of 2017. [67] [68] [69] The VHA has employed a multifaceted, integrated approach, including the formation of regional HCV innovation teams focused on increasing birth cohort testing, adoption of a national HCV testing electronic clinical reminder, establishing HCV testing as a regional and national VA quality performance metric, and publishing quarterly reporting of HCV birth cohort testing rates at site, regional, and national levels to enhance transparency and accountability. 68 Many of these strategies may potentially be applicable to large non-federal health systems but requires high-level engagement by leadership and institutional commitment to achieving similar levels of success.
POCT and rapid detecting tests (RDTs)
The CDC and USPSTF guidelines recommend that HCV Ab testing should be performed as a screening test of choice, and positive results should be reflexed to HCV RNA test by PCR or nucleic acid testing. 70, 71 The gold standard test for anti-HCV identification has been the enzyme immunoassay, which takes several days to weeks to process a result, and has significant laboratory requirements, including high-cost equipment, trained technicians, continuous supply of electricity and high facility cost. In contrast, newer rapid point-of-care immunoassays can provide results in as little as 20-40 m. The OraQuick test represents the most widely used POCT in the USA, approved by the Federal Drug Administration in 2010, and can detect HCV Ab in saliva or blood. 72 One meta-analysis reported a pooled sensitivity of 98% (95% confidence interval: 98-100%) and specificity of 100% (95% confidence interval: 100-110%) for HCV Ab rapid diagnostic test compared to the enzyme immunoassay reference standard. Another pooled analysis of eight studies demonstrated that OraQuick ADVANCE was associated with a sensitivity of 98% compared to 88% with other oral assays. 73 RDTs are often faster than POCTs but require specialized equipment and specially trained personnel, are limited to HCV Ab detection (unable to detect HCV RNA), and associated with lower diagnostic performance than POCTs. 74 Further studies to define optimal use of POCTs and RDTs may be helpful in identifying their appropriate role in HCV screening efforts.
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Future directions
Despite major advances in antiviral therapy for chronic HCV infection since 2014, persistent deficits in the HCV care cascade within the USA threaten to limit the capacity to achieve meaningful changes in the burden of chronic infection and downstream clinical outcomes, as well as ambitious targets for HCV elimination by the WHO and USA Department of Health and Human Services. Although progress has been made within each step of the cascade, including screening (HCV Ab), confirmation (HCV RNA), linkage to care, and treatment, identification of uninfected patients represents the critical rate-limiting step. Additional challenges to achieving HCV elimination include ongoing late relapse and reinfection among patients who achieve sustained virologic response.
Since implementation of new recommendations for onetime HCV Ab testing in all USA adults born 1945-1965 by the CDC and USPSTF, birth cohort screening has provided a central focus for health system, state, and national level efforts to increase the diagnosis of chronic HCV. A multifaceted integrative approach to screening which integrates clinical education, clinical decision support, reflex HCV RNA testing, and incorporation of non-physician providers have been proven to be successful in increasing HCV screening. However, multiple studies have confirmed that overall screening rates within the USA outside the VHA remain low, despite success within individual centers and health systems. Based on the available literature, no single strategy appears to be easily applicable across clinical settings.
Our review underscores the need for the following steps: 1) patient and provider education to address a persistent deficit in knowledge, regarding both HCV risk factors as well as national screening recommendations; 2) engagement of health systems to incorporate standardized tools, such as reflex HCV RNA testing and EMR alerts to prompt clinicians to pursue HCV testing across the inpatient, emergency department, outpatient clinic, pharmacy, and endoscopy center settings; and 3) strategic use of novel diagnostic tests (e.g. POCT/RDT) and emerging technologies (e.g. text alerts) in appropriate clinical settings. Significant resources may be required to fully support the multidisciplinary programs required to meaningfully impact broader efforts for screening, linkage to care, and treatment.
Furthermore, emerging data suggest that birth cohort screening will be inadequate to identify the growing cohort of non-birth cohort adults with chronic HCV, including a rising population of young adults recently infected with HCV in the context of substance use and the opiate epidemic. Recent NHANES reports suggest an overall decrease in chronic HCV prevalence from 1.32% to 0.80% between 1999-2004 and 2011-2016; although, an estimated 1.90 million USA adults continued to have viremic HCV, of whom only 49.8% were reportedly aware of their infection. 75 An updated report which combined NHANES data with high-risk populations excluded by NHANES (prisoners, unsheltered homeless persons, active-duty military personnel, nursing home residents) estimated a prevalence of 2.4 million HCV RNA-positive persons. 2 Expansion from birth cohort to universal screening of all USA adults may identify up to an estimated 28% of HCV-infected individuals who would be missed by birth cohort [55] [56] [57] [58] [59] [60] or risk factor-based screening strategies. 76 In addition, economic models have demonstrated that a universal screening strategy in USA adults is more cost effective than a birth cohort screening strategy in populations with a HCV prevalence >0.07% among non-birth cohort adults. 77 This emerging evidence of increasing HCV incidence in younger adults 78 and resulting gap in identification of HCV-infected persons have prompted reconsideration of USA HCV screening guidelines.
In 2019, several organizations have publicly called for expansion of HCV screening to a universal approach to offer one-time HCV Ab testing to all USA adults age 18-79 years or age 18 years and older, including draft statements by the USPSTF (August 2019) 79 and CDC (October 2019), 80 as well as updated language within the HCV guidance document of the Infectious Diseases Society of America and American Association for the Study of Liver Diseases (November 2019). 81 In the context of these emerging changes in national screening recommendations, significant additional research is needed to support evidence-based recommendations on population and system-level HCV screening strategies. Lessons learned from early experiences with birth cohort screening studies may help inform future research and public health efforts at implementation of future universal screening initiatives.
